To The Moon

Forty-four U.S. stocks with market caps above $10 billion are trading at fresh all-time highs as of June 30, 2026. The top 10 span pharmaceuticals, semiconductor equipment, cybersecurity, optical communications, and Canadian banking — a cross-section of the market's strongest narratives right now.

The top 10 tickers leading this cohort — $Eli Lilly(LLY)$, $Johnson & Johnson(JNJ)$, $Applied Materials(AMAT)$, $Lam Research(LRCX)$, $AbbVie(ABBV)$, $KLA-Tencor(KLAC)$, $Royal Bank of Canada(RY)$, $Palo Alto Networks(PANW)$, $Corning(GLW)$, $Bank of Montreal(BMO)$.

🧭 Key Market Drivers

• GLP-1 Dominance & Pharma Re-Rating: Eli Lilly and Johnson & Johnson are leading a pharmaceutical rally driven by obesity-drug demand and defensive cash-flow profiles. LLY's GLP-1 franchise is approaching $50B annual run-rate revenue, while JNJ's diversified med-tech and pharma mix continues to attract safety-seeking capital.

• AI Infrastructure Capex Cycle: Applied Materials, Lam Research, and KLA Corporation are the picks-and-shovels beneficiaries of the AI semiconductor buildout. All three are posting record revenues and receiving aggressive price-target hikes as wafer-fab-equipment spending extends into 2028.

• Cybersecurity Consolidation & Platform Shift: Palo Alto Networks is capitalizing on the industry-wide shift toward consolidated security platforms. Its Q3 beat and raised full-year guidance signal that platformization is translating into both top-line acceleration and margin expansion.

• Optical & Materials Science AI Enablers: Corning is riding AI-driven hyperscale demand for fiber and connectivity solutions, while Canadian banks RY and BMO benefit from resilient North American credit quality and capital-return programs.

1. $Eli Lilly(LLY)$

• Core Business:

Global pharmaceutical leader focused on diabetes, obesity, oncology, and immunology. Its GLP-1 franchise (Mounjaro and Zepbound) has become the dominant revenue driver.

• Latest Developments:

In Q1 2026, Lilly reported nearly $13 billion in combined quarterly revenue from Mounjaro and Zepbound, with the company controlling roughly 60% of the U.S. GLP-1 market. International sales of incretin medicines surged 81% year over year to $7.7 billion, as Mounjaro launched across Europe, the Middle East, Asia, and Latin America. France became the first major EU country to approve reimbursement for obesity treatments.

• Latest Earnings Highlights:

Q1 2026 Financial Highlights: Revenue was $19.8 billion; earnings reached $7.66 billion; diluted EPS (TTM) was $28.17. The company trades at a P/E of 44.3x with EPS growing 130.14% year over year.

• Price Target Outlook:

Leerink Partners maintained an "Outperform" rating on June 25, 2026, raising the price target from $1,119 to $1,232. Consensus rating is Strong Buy.

2. $Johnson & Johnson(JNJ)$

• Core Business:

Diversified healthcare conglomerate spanning innovative medicine (pharmaceuticals), med-tech (surgical robotics, orthopedics), and consumer health products.

• Latest Developments:

On June 26, 2026, Guggenheim raised its price target from $266 to $270 while maintaining a "Buy" rating. The company recently announced a $1 billion acquisition of Firefly Bio to bolster its oncology pipeline. Positive Phase 2/3 ENERGY study results for Imaavy (a rare disease therapy) increased the likelihood of FDA approval. However, a $32 million jury ruling in ongoing talc litigation added headline risk.

• Latest Earnings Highlights:

Q1 2026 Financial Highlights: Revenue was $24.06 billion; earnings were $6.61 billion; diluted EPS (TTM) was $8.63. The stock trades at a P/E of 29.9x. YTD return stands at 24.99%.

• Price Target Outlook:

Guggenheim analyst maintained a "Buy" rating, raising the price target from $266 to $270 on June 26, 2026. Consensus rating is Strong Buy with an average price target of $257.50.

3. $Applied Materials(AMAT)$

• Core Business:

The world's largest semiconductor equipment company, providing materials engineering solutions for chip manufacturing, including deposition, etch, metrology, inspection, and advanced packaging.

• Latest Developments:

On June 25, 2026, Applied Materials introduced a suite of new chipmaking systems designed to build advanced 3D chip architectures powering next-generation AI. The company expects packaging revenues to grow more than 50% in calendar 2026. On June 23, BofA raised its price target from $540 to $720, maintaining a "Buy" rating. On June 26, Wells Fargo raised its target from $715 to $740, reiterating an "Overweight" rating.

• Latest Earnings Highlights:

Q2 FY2026 Financial Highlights: Revenue was a record $7.91 billion, up 11% year over year; non-GAAP EPS was a record $2.86, up 20% year over year. The company trades at a P/E of 65.3x with EPS growing 29.54% year over year. YTD return is 160.09%.

• Price Target Outlook:

BofA raised its price target from $540 to $720 on June 23, 2026, maintaining a "Buy" rating. Wells Fargo raised its target from $715 to $740 on June 26, 2026, reiterating "Overweight." Consensus rating is Strong Buy.

4. $Lam Research(LRCX)$

• Core Business:

Leading provider of wafer fabrication equipment, specializing in etch and deposition systems used in the manufacturing of advanced semiconductors, with a growing advanced packaging business.

• Latest Developments:

On June 29, 2026, Cantor Fitzgerald analyst C.J. Muse raised the price target from $425 to $500 while maintaining an "Overweight" rating, citing the semiconductor equipment sector being in the "early innings of a multi-year supply-constrained and durable upcycle." On June 11, Barclays analyst Tom O'Malley raised his target from $275 to $335. On June 9, UBS analyst Timothy Arcuri raised his target from $310 to $375. The company opened a new Boise office to support Micron's memory expansion and is projecting more than 50% advanced packaging revenue growth in 2026.

• Latest Earnings Highlights:

Q3 FY2026 Financial Highlights: Revenue was $5.84 billion; earnings were $1.85 billion; diluted EPS (TTM) was $5.31. The company trades at a P/E of 77.6x with EPS growing 47.60% year over year. YTD return is 131.04%.

• Price Target Outlook:

Cantor Fitzgerald's C.J. Muse raised the price target from $425 to $500 on June 29, 2026, maintaining "Overweight." Barclays' Tom O'Malley raised his target from $275 to $335 on June 11, 2026. UBS's Timothy Arcuri raised his target from $310 to $375 on June 9, 2026. Consensus rating is Strong Buy.

5. $AbbVie(ABBV)$

• Core Business:

Research-based biopharmaceutical company focused on immunology (Skyrizi, Rinvoq), oncology, neuroscience, and aesthetics, with a rapidly growing pipeline offsetting Humira biosimilar erosion.

• Latest Developments:

On May 5, 2026, AbbVie presented 18 abstracts at the Digestive Disease Week Annual Meeting, highlighting long-term efficacy data for Skyrizi and Rinvoq in Crohn's disease and ulcerative colitis. The NHS approved Elahere for platinum-resistant ovarian cancer. The European Commission approved atogepant for migraine treatment. The FDA approved Decnupaz for BPDCN (blastic plasmacytoid dendritic cell neoplasm). On June 23, Piper Sandler reiterated an "Overweight" rating with a $298 price target.

• Latest Earnings Highlights:

Q1 2026 Financial Highlights: Revenue was $15.0 billion; earnings were $4.71 billion; diluted EPS was $2.65 (vs. consensus estimate of $2.67). The company trades at a P/E of 125.4x with EPS declining 13.55% year over year, though forward P/E is 17.79x. YTD return is 11.18%.

• Price Target Outlook:

Piper Sandler reiterated an "Overweight" rating on June 23, 2026, maintaining a $298 price target. Consensus rating is Strong Buy with an average price target of $254.38.

6. $KLA-Tencor(KLAC)$

• Core Business:

The dominant player in process control, wafer inspection, and yield management solutions for semiconductor manufacturing, critical for ensuring chip quality at advanced nodes.

• Latest Developments:

On June 29, 2026, Cantor Fitzgerald raised its price target from $250 to $325 while maintaining an "Overweight" rating. The company completed a 10-for-1 stock split on June 12, 2026. KLA remains the essential process-control gatekeeper as AI-driven logic and memory investments accelerate, with leading-edge foundry and logic accounting for the majority of new wafer-start investments in 2026 and 2027.

• Latest Earnings Highlights:

Q3 FY2026 Financial Highlights: Revenue was $3.42 billion; earnings were $1.24 billion; diluted EPS (TTM) was $3.95. The company trades at a P/E of 78.7x with EPS growing 28.55% year over year. YTD return is 121.00%.

• Price Target Outlook:

Cantor Fitzgerald raised its price target from $250 to $325 on June 29, 2026, maintaining an "Overweight" rating. Consensus rating is Strong Buy.

7. $Royal Bank of Canada(RY)$

• Core Business:

Canada's largest bank by market capitalization, operating across personal banking, commercial banking, wealth management, insurance, and capital markets, with significant U.S. operations.

• Latest Developments:

On June 10, 2026, Royal Bank announced that the Toronto Stock Exchange and OSFI approved its normal course issuer bid to repurchase up to 45 million common shares (approximately 3.24% of shares outstanding) from June 12, 2026 to June 11, 2027. The bank's previous bid repurchased 19.17 million shares at a volume-weighted average price of approximately $215.85. On June 26, 2026, the bank was fined $4.25 million over inaccurate credit card statements.

• Latest Earnings Highlights:

Q2 FY2026 Financial Highlights (period ended April 30, 2026): Revenue was CAD $17.45 billion; earnings were CAD $5.45 billion. The bank trades at a P/E of 18.1x with EPS growing 24.34% year over year. YTD return is 19.59%.

• Price Target Outlook:

Argus Research maintained a "Buy" rating on August 29, 2025, raising the price target from $140 to $162. Consensus rating is Strong Buy.

8. $Palo Alto Networks(PANW)$

• Core Business:

Leading cybersecurity platform company providing network security, cloud security, and security operations solutions, driving the industry shift toward consolidated security platforms.

• Latest Developments:

On June 2, 2026, Palo Alto Networks reported Q3 FY2026 results, with EPS of $0.85 beating consensus estimates of $0.79-$0.81 by $0.04-$0.06. Revenue was $3.0 billion, up 31.1% year over year and above the $2.94 billion consensus. The company raised its full-year FY2026 guidance to revenue of $11.4 billion and EPS of $3.77-$3.79, compared to prior consensus of $11.3 billion revenue and $3.38 EPS. On June 3, Citigroup raised its price target from $210 to $340 while maintaining a "Buy" rating.

• Latest Earnings Highlights:

Q3 FY2026 Financial Highlights: Revenue was $3.0 billion (+31.1% YoY); earnings were $684 million; diluted EPS was $0.85 vs. consensus $0.79. The company trades at a P/E of 273.1x with EPS declining 30.43% year over year on a trailing basis, though forward P/E is 74.63x. YTD return is 79.64%.

• Price Target Outlook:

Citigroup analyst maintained a "Buy" rating on June 3, 2026, raising the price target from $210 to $340. Consensus rating is Strong Buy.

9. $Corning(GLW)$

• Core Business:

Materials science company specializing in optical communications (fiber, cable, connectivity), display technologies, specialty materials (including semiconductor materials), automotive, and life sciences.

• Latest Developments:

On May 6, 2026, Corning held its Investor Day in New York City, unveiling a photonic MAP as part of its new optical infrastructure growth plan for AI from 2027 to 2030. Management set annual sales targets of $30 billion by year-end 2028 and $40 billion by year-end 2030. The company signed two additional long-term agreements with hyperscale customers. On June 22, Truist Securities raised its price target from $149 to $205 while maintaining a "Hold" rating. On May 7, Oppenheimer analyst Martin Yang raised his target from $120 to $210, maintaining a "Buy" rating.

• Latest Earnings Highlights:

Q1 2026 Financial Highlights: Revenue was $4.34 billion (+18.1% YoY); earnings were $612 million; diluted EPS was $0.70, exceeding analyst expectations. Operating margin improved by 220 basis points to 20.2%. The company trades at a P/E of 122.7x with EPS surging 298.68% year over year. YTD return is 187.58%.

• Price Target Outlook:

Truist Securities raised its price target from $149 to $205 on June 22, 2026, maintaining a "Hold" rating. Oppenheimer's Martin Yang raised his target from $120 to $210 on May 7, 2026, maintaining "Buy." JP Morgan's Samik Chatterjee raised his target from $175 to $185 on May 7, 2026, maintaining "Hold." Consensus rating is Strong Buy.

10. $Bank of Montreal(BMO)$

• Core Business:

One of North America's largest diversified financial services providers, with operations in Canada and the United States across personal and commercial banking, wealth management, and capital markets.

• Latest Developments:

On May 28, 2026, RBC Capital maintained a "Sector Perform" rating while raising its price target from $205 to $230. The bank continues to benefit from resilient North American credit quality and strong capital markets activity. BMO's YTD return of 35.27% significantly outperforms the S&P/TSX Composite Index's 9.34% gain.

• Latest Earnings Highlights:

Q2 FY2026 Financial Highlights: Revenue was $9.57 billion; earnings were $2.59 billion; diluted EPS (TTM) was $9.14. The bank trades at a P/E of 18.4x with EPS growing 22.93% year over year. YTD return is 35.27%.

• Price Target Outlook:

RBC Capital maintained a "Sector Perform" rating on May 28, 2026, raising the price target from $205 to $230. Consensus rating is Buy.